2021 Diabetes Insurance Coverage and Processing 
pharmaphorum
JANUARY 28, 2021
It’s important that the biosimilar market continue to build on the success established last year in 2021. Based on this momentum, we’re making three predictions for 2021: we will see increased competition within individual markets pay off, expansion in the biosimilar channel to include new therapeutic categories, and more regulatory support.
pharmaphorum
FEBRUARY 4, 2022
Lilly is a little vague on when it will now file donanemab with the FDA – suggesting on its fourth quarter 2021 results call that it may do so later this year – but reiterated that it has little hope of the drug being used ahead of the readout of TRAILBLAZER-ALZ 2 in mid-2023. Trulicity contributed $1.9
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
NOVEMBER 30, 2022
The drug was approved to treat type 2 diabetes mellitus in May. High rates of obesity place a major burden on healthcare systems as the condition is associated with many major health complications like type 2 diabetes, hypertension, non-alcoholic fatty liver disease, and other bodily dysfunctions. Anti-obesity therapeutic landscape.
Pharmaceutical Technology
NOVEMBER 30, 2022
The drug was approved to treat type 2 diabetes mellitus in May. High rates of obesity place a major burden on healthcare systems as the condition is associated with many major health complications like type 2 diabetes, hypertension, non-alcoholic fatty liver disease, and other bodily dysfunctions. Anti-obesity therapeutic landscape.
Putting Patients First Blog
JANUARY 10, 2024
Making available more specific information about total costs and coverage will ensure that all consumers have comprehensive information to help them make smart health care decisions. These resources should aim to clarify insurance terms and concepts, aiding consumers in navigating the complexities of selecting a health plan.
pharmaphorum
OCTOBER 7, 2021
Milan, Italy | October 5, 2021 – Originally published in January 2021 for Italian audiences, the international, updated version of “DTx: An Opportunity for Italy and Beyond” is now available in English.
Putting Patients First Blog
JULY 2, 2024
We believe that patient-centric engagement is essential to ensure that the negotiation process leads to outcomes that genuinely benefit patients. Patient Engagement The NHC recognizes and commends CMS’ willingness to improve the listening sessions and the data submission processes. Improving the Data Collection (ICR) Process.
Expert insights. Personalized for you.
119 
Let's personalize your content